Latest news with #Transmed
The Citizen
23-05-2025
- Business
- The Citizen
Trio of medical aids fail to maintain required liquidity
Medihelp, Sizwe Hosmed and Transmed solvency ratios all below 25% – Council for Medical Schemes. The solvency rate across the industry is down, but at 43% is significantly higher than the required minimum. Picture: AdobeStock Three medical aid schemes – Medihelp, Sizwe Hosmed Medical Scheme and Transmed Medical Fund – failed to maintain their solvency ratios at or above 25% in 2023, the minimum statutory prescribed level in the Medical Schemes Act. This is revealed in the Council for Medical Schemes (CMS) Financial Performance Industry Report 2023 released this week. Transmed improved its solvency ratio to 23.79% in 2023 from 17.7% in 2022 but this is at least the fourth consecutive year it has failed to comply with the statutory prescribed solvency ratio after achieving a liquidity ratio of 19.72% in 2021 and 22.37% in 2020. Sizwe Hosmed failed to meet the prescribed solvency level in 2023, with its solvency ratio deteriorating to 15.73% in 2023 from 25.59% in 2022. Medihelp's solvency ratio deteriorated to 23.84% in 2023 from 33.93% in 2022. The report said these three schemes account for 4.11% of all medical scheme beneficiaries. The number of medical aid beneficiaries in South Africa increased from 9 039 259 in 2022 to 9 127 453 in 2023, but only 14.7% of the population was covered by medical aid schemes in 2023 compared to 16% in 2000. The solvency ratio of a medical aid scheme refers to the accumulated funds of a scheme as a percentage of its gross annual contributions. Moneyweb requested an update from the CMS on the liquidity ratio status of Medihelp, Sizwe Hosmed and Transmed but a response has not yet been received. ALSO READ: Why you shouldn't wait before joining a medical aid scheme Industry-wide view The report said the solvency ratios of both open and restricted schemes deteriorated in 2023. CMS chief executive and registrar Dr Musa Gumede said in the report that despite medical schemes incurring a net surplus for the year, due to the mathematical calculation used, the industry solvency declined from 47.14% in 2022 to 43.45% in 2023. Gumede said it is expected the solvency level will continue to decrease in the next few years due to the denominator representing the increased level of contributions before stabilising. He added that the 2023 solvency of 43.45% does however exceed pre-Covid-19 pandemic levels of 34.54% in 2018 and 35.61% in 2019 – and is also significantly higher than the minimum required level of 25%. Gumede added that 'relevant healthcare expenditure' (claims) per average beneficiary per month continued to increase above inflation in 2023 – rising 8.7% from R1 840.48 in 2022 to R2 000.57. These claims were escalating pre-Covid-19 and it is expected this trend, which was interrupted by the pandemic, will continue unless drastic interventions are made. ALSO READ: Increasing medical aid scheme costs: What are the alternatives? Gumede said increased expenditure is a function of changes in utilisation and tariffs, with utilisation increases closely linked to the worsening demographic profile of medical schemes. He said medical scheme membership grew by only 1.04% in 2023 while the average age of beneficiaries increased by 0.27 years. 'The aftermath of Covid-19 continued to impact medical schemes during the 2023 financial year. 'Increased utilisation due to the release of pent-up demand was noted across the industry. 'Based on monthly indicator information submitted during 2024, the increased levels of utilisation continued in 2024 and had to be factored into the 2025 year's contribution increases,' he said. Gumede said schemes implemented contribution increases below consumer inflation during the 2021 and 2022 financial years to provide temporary financial relief to members during the economic downturn. Schemes were able to implement these interventions due to reserves built up during the Covid-19 pandemic. However, Gumede said the lower contribution increases resulted in underpricing at an insurance service result level, resulting in a deficit of R6.73 billion for the 2023 financial year, which will need to be addressed and corrected in the coming years. Gumede said the CMS has encouraged medical schemes to correct the pricing over a period rather than implementing it as a single, large corrective event. ALSO READ: Watch out: medical aid scheme surprises that can cost you money Sizwe Hosmed The report said Sizwe Hosmed Medical Scheme's increase in relevant healthcare expenditure outpaced the increase in its contributions. It said the scheme experienced an increase of 17.19% in the relevant healthcare expenditure per average beneficiary per month (pabpm) in 2022, with a further increase of 4.12% pabpm in 2023, compared to the actual insurance revenue increase of 2.83% pabpm. The report said the scheme fell below the minimum required solvency level at the beginning of 2023 and has submitted three business plans during the financial year. It said the first business plan was retracted by the scheme, the second was rejected due to, among other things, the appropriateness of the claims assumptions to which the scheme was unable to respond. The scheme subsequently appointed a new actuary with medical scheme-specific experience and a third business plan was submitted together with its 2024 year's pricing. The report said the scheme subsequently had to realign this submission with its pricing submission. 'This business plan was subsequently rejected as the 2023 actual results differed significantly from the projections – and cast aspersions on whether the scheme understood its underlying claims make-up,' it said. The report said the CMS requested further actuarial claims analysis to be submitted, and the board of trustees and registrar agreed to the appointment of a statutory manager. It said the scheme's business plan for the 2025 year has been approved by the registrar. ALSO READ: How to make the most of your medical aid scheme Transmed The CMS said Transmed Medical Fund has a worse demographic profile than the industry average. It said schemes with higher demographic profiles are at particular risk of the so-called 'death spiral', where adjustments to pricing for the profile of its members might result in the unaffordability of contributions and the subsequent loss of its younger members, therefore exacerbating the effect. The report said the employer group provides specific funding for the scheme's Guardian option, which had a pensioner ratio of 94.53% and a relevant healthcare expenditure ratio of 84.84% at the end of 2023. It said that with the exception of the Prime option, the remainder of the options incurred insurance service surpluses in 2023. The Prime option only has 237 beneficiaries, with an average age of 75.51 years and a pensioner ratio of 83.54%, it said. The registrar approved the scheme's business plan for the 2024 and 2025 years. ALSO READ: Gap cover analysis shows massive erosion of medical scheme benefits Medihelp The report said Medihelp deliberately underpriced its benefits during the Covid-19 pandemic in an attempt to provide relief to its members. The scheme experienced a 3.89% decrease in its insurance revenue pabpm from 2021 to 2022, compared to an average CPI of 6.9% during the same period, and an increase of 3.51% in its insurance revenue pabpm. The report said the scheme corrected its pricing for the 2024 financial year and submitted the required business plan, which was subsequently approved by the registrar. This article was republished from Moneyweb. Read the original here.
Zawya
15-05-2025
- Business
- Zawya
AUS–Transmed MoU paves the way for purposeful industry engagement
Sharjah, UAE – American University of Sharjah (AUS) has signed a Memorandum of Understanding (MoU) with Transmed, a privately owned company with a strong regional presence in the distribution of consumer goods, including household, personal care and food products. The agreement sets the stage for collaboration in research, student development and knowledge exchange, aligning academic insight with industry practice to benefit both institutions and the broader community. The MoU was signed by Dr. Tod Laursen, Chancellor of AUS, and Dr. Ahmad Mourad, Chief Information Officer of Transmed, in the presence of senior officials from both institutions. 'Strong university-industry linkages are essential to delivering education that is both rigorous and relevant. This MoU with Transmed gives our students and faculty access to valuable real-world contexts while enabling Transmed to benefit from emerging research and fresh thinking. We look forward to seeing this relationship grow in a way that brings value to both organizations and contributes meaningfully to the wider community,' said Dr. Laursen. The MoU sets the foundation for a long-term partnership designed to foster applied research, industry-informed learning and hands-on professional experiences in areas that are shaping the future of work and enterprise. These include intelligent systems, data-driven decision-making, innovation practices and business strategy. The scope of collaboration spans joint research and publications, real-world use cases for AUS student capstone projects, and internship and employment opportunities for students and alumni. 'As an FMCG and distribution leader for global brands, Transmed recognizes the transformative power of integrating human talents, technology, artificial intelligence, and business processes and the need to connect academic research with real-world industry applications. We firmly believe that great innovation happens at the intersection of academia and industry and today marks the beginning of an exciting journey together. AUS has a strong reputation for academic excellence, and Transmed is proud to contribute to shaping the future of its students,' said Dr. Ahmad Mourad, Chief Information Officer of Transmed. 'This MoU represents a shared commitment to knowledge exchange, talent development and innovation by bridging industry and academia. This collaboration is designed to empower AUS students with hands-on industry experience, provide practical insights into business challenges and create a stronger talent pipeline that will drive both innovation and economic growth,' said Georges Bejjani, Corporate Human Resources Director at Transmed. The collaboration also supports knowledge exchange, joint participation in career fairs, mutual visits and the co-organization of conferences, workshops and seminars, further strengthening the link between academic inquiry and industry application. This strategic collaboration is part of AUS' broader mission to foster purposeful engagement between academia and industry. By integrating research and education with practical application, the university creates opportunities for innovation, meaningful student learning and faculty research that contributes to real-world progress. To learn more about AUS, visit
